NVAX Climbs Almost 8% For the Day
Novavax (NVAX) rose around 8% on the news of a new study; a Covid-19 booster study in adolescents aged between 12 and 17 years old.
Initial data from the pediatric expansion study is anticipated during the second half of 2022. The objectives of the study will assess the humoral immune response in participants after 28 days of receiving the third dose.
NVAX is a part of the PRISM Vaccines & Cell Therapy Index which is up 1.4% for the day.
About Novavax Novavax, Inc.
(Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its quadrivalent influenza investigational vaccine candidate previously known as NanoFlu*. These vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
